Định lượng HBV-DNA và xác định đột biến kháng thuốc ở những bệnh nhân có vi rút viêm gan B mãn tính (HBV) ở tỉnh Hải Dương

The purposes of the paper are i) To survey quantitative HBV-DNA in patients with HBsAg + (Hepatitis B surface antigen positive) with antiretroviral drugs and ii) To determine drug resistant mutants in the Pre-S and RT regions in patients with quantitative HBV-DNA 104 copies/mL 6 months after treatment. 195 patients with chronic hepatitis were treated with antiretroviral drugs, periodically examined and tested for biochemical indices; quantitative HBV-DNA was carried out 6 months before treatment and every 3 months after treatment. After being treated for 6 months, patients with quantitative HBV-DNA 104 copies/mL would be determined to have drug resistant mutants in the RT and Pre-S regions. Group of patients with quantitative HBV-DNA levels 106 copies/mL decreased from 67.7 percent (pre-treatment) to 4.6 percent after 3 months of treatment and 8.7 percent after 6 months of treatment; group of patients with quantitative HBV DNA positive under detection increased from 0 percent (pre-treatment) to 15.9 percent after 3 months of treatment and 78.5 percent after 6 months of treatment; 17/195 patients with quantitative HBV-DNA decreased but possibly flared up again. These samples carried mutations in the RT and Pre-S regions. The result showed that 9/17 specimens had mutations in the region RT. There were no mutations in Pre-S. Most of the patients were in serious disease condititon before treatment. This resulted in 67.7 percent of patients with quantitative HBV-DNA 106 copies/mL.